logo
Plus   Neg
Share
Email

Nutrien Issues 2020 Earnings Guidance - Quick Facts

Nutrien Ltd. (NTR,NTR.TO) said, for 2020, it expects adjusted net earnings of $1.90 to $2.60 per share and adjusted EBITDA of $3.8 billion to $4.3 billion. Analysts polled by Thomson Reuters expect the company to report profit per share of $3.04. Analysts' estimates typically exclude special items.

Fourth-quarter adjusted net earnings was $0.09 per share. On average, ten analysts polled by Thomson Reuters expected the company to report profit per share of $0.29, for the quarter. Adjusted EBITDA declined 28% to $664 million from previous year.

Fourth-quarter sales declined 9% year-on-year to $3.44 billion. Analysts expected revenue of $3.99 billion for the quarter.

Shares of Nutrien Ltd. were down 3% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) expects that its first-quarter operating profit will increase about 2.73 percent from last year, sales will also increase 4.98 percent. JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered.
RELATED NEWS
Follow RTT
>